Beam Therapeutics filed suit accusing YolTech Therapeutics and Serapha Bio of stealing base-editing intellectual property, alleging that a former Beam scientist co-founded YolTech while still employed. Beam claims Zi Jun “Emma” Wang accessed confidential information, including electronic laboratory notebooks, before launching the YolTech effort. Beam further alleges that YolTech’s work and a subsequent therapy licensed to Serapha incorporate proprietary technology tied to Beam’s rare disease program. The lawsuit also frames the dispute within escalating US-China biotechnology tensions, spotlighting how rapidly trading teams can turn into platform competition for intellectual property-heavy tools like base editing. YolTech and Serapha deny the allegations, setting up a high-stakes test for patent coverage, trade secret protections, and the evidentiary bar in cross-border biotech disputes.